Diagnostyka S.A. Reports Strong Q1 2026 Financial Performance Amid Strategic Growth and Market Expansion
Kraków, Poland – May 28, 2026: Diagnostyka S.A., a leading Polish healthcare diagnostics group, has reported robust financial results for the first quarter of 2026, driven by strategic acquisitions, organic growth, and increased demand for diagnostic services. The company achieved a 14.6% year-on-year (YoY) increase in operational revenue, reaching PLN 681.6 million, while net profit attributable to shareholders rose by 13.3% YoY to PLN 82.6 million. The Group also recorded a 1.2% YoY increase in test volumes, totaling 45.8 million tests, alongside a 16.5% rise in the average price of diagnostic tests.
Key developments in Q1 2026 included the acquisition of 61% of Skamed Rezonans (diagnostic imaging), 75% of PP Diagnostyka Sp. z o.o. (diagnostic imaging), and 100% of LAB-AD and Instytut Mikroekologii (both in laboratory diagnostics). Additionally, Diagnostyka acquired several organized parts of enterprises (ZCPs) to strengthen its market position in laboratory diagnostics. The company also continued its participation in national health programs, including "Moje Zdrowie" and the Cervical Cancer Prevention Program, further solidifying its role in Poland's healthcare system.
Diagnostyka invested significantly in infrastructure, including the development of modern laboratories in Gdynia and Gliwice, and launched a new integrated ERP system, SAP, to enhance operational efficiency. The company also announced a dividend payout of PLN 4.40 per share, totaling PLN 148.5 million, approved by its General Meeting on May 25, 2026.
Despite facing challenges such as rising operational costs and wage pressures, Diagnostyka remains optimistic about its growth prospects, driven by market trends such as increasing demand for diagnostic services, aging demographics, and advancements in automation and artificial intelligence.
Relevance to Diagnostyka S.A.: The article highlights Diagnostyka S.A.'s strong financial performance, strategic acquisitions, and market expansion, aligning with its business model of growth through acquisitions, infrastructure development, and increased demand for diagnostic services.